US EditionSwiss pharma company Galenica to cut up to 170 jobs at Bichsel
9 Articles
9 Articles
Swiss pharma company Galenica to cut up to 170 jobs at Bichsel
Drug wholesaler and pharmacy operator Galenica is to cease pharmaceutical production at its subsidiary Bichsel by the end of the year, citing a lack of competitiveness. This measure will result in the loss of up to 170 jobs by the end of 2026.
Invoking a lack of competitiveness, the drug wholesaler announced that by the end of the year the pharmaceutical production subsidiary would close.A consultation to maintain jobs is planned next monthThe drug wholesaler and operator of Galenica pharmacies will stop by the end of the year the pharmaceutical production of its subsidiary Bichsel, citing a lack of competitiveness.With this measure, up to 170 posts will be abolished by the end of the…
The company Galenica ceases the pharmaceutical production of its daughter Bichsel in Interlaken until the end of 2026.
Handelszeitung
MoneycabThe health company Galenica closes the pharmaceutical production Bichsel in Interlaken by the end of 2026 at the latest. Up to 170 jobs are affected.
The pharmaceutical wholesaler and pharmacy chain Galenica has announced it will cease pharmaceutical production at its subsidiary Bichsel by the end of the year, citing a lack of competitiveness. This measure directly threatens 170 jobs.
The drug wholesaler and pharmacy operator Galenica will stop the pharmaceutical production of its subsidiary Bichsel by the end of the year. The company based in Bern claims a lack of competitiveness. With this measure, up to 170 posts will be abolished by the end of 2026.
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
